# nykode

therapeutics

**Corporate Presentation** 

SVB Leerink 11th Annual Global Healthcare Conference

February 18, 2022



### **Forward-looking statement**


This announcement and any materials distributed in connection with this presentation may contain certain forwardlooking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.



### **Overview**

- Proprietary Vaccibody<sup>™</sup> immunotherapy platform uniquely targets Antigen Presenting Cells (APCs) for a potent, broad and lasting immune response
- Pipeline of oncology and infectious disease vaccines includes partnered programs and wholly-owned clinical candidates
- Potentially more than \$1.64 billion in upfront and milestone payments plus royalties from top-tier biopharma partners
- Wholly-owned programs include cervical cancer candidate in Phase 2; next generation COVID vaccine for variants of concern in Phase 1/2
- Well capitalized and multiple significant catalysts in near-to-medium term



### Top-tier collaborations for cancer and infectious disease vaccines valued potentially more than \$1.64 billion plus royalties

Partner	Collaboration	Terms	Clinical Development		
REGENERON	Multi-target license and collaboration agreement to develop 3 oncology and 2 novel infectious disease programs	<ul> <li>\$925M~</li> <li>\$30M upfront</li> <li>\$20M equity investment</li> <li>Potentially more than \$875M in milestone payments</li> <li>Tiered high single-digit to low double-digit royalties</li> </ul>	Regeneron to develop and potentially commercialize products Nykode to supply technology and product supply through Phase 1 trials		
<b>Genentech</b> A Member of the Roche Group	Worldwide, exclusive license and collaboration agreement to develop VB10.NEO, Nykode's individualized neoantigen cancer vaccine	<ul> <li>\$715M~</li> <li>\$200M upfront/near term</li> <li>\$515M in potential payments and milestones</li> <li>Tiered low double-digit royalties</li> </ul>	Nykode to conduct clinical trials through Phase 1b study Genentech to subsequently conduct clinical, regulatory, manufacturing and commercialization activities		
Adaptive biotechnologies"	Worldwide, exclusive rights to Adaptive's clinically validated SARS-CoV-2 T cell epitopes	Undisclosed	Nykode to design and develop T cell vaccines to specifically address SARS-CoV-2 variants of concern		

### **Pipeline**


		Program	Indication	Discovery/ Preclinical	Phase 1	Phase 2	Phase 3	Partnerships	Upcoming Milestones
	Nykode								
	Oncology	VB10.16 (off-the-shelf)	HPV16+ cervical cancer <sup>3</sup>						1H22: Interim Data
		Internal (off-the-shelf)	Undisclosed targets						
	Infectious Disease	VB10.COV2	SARS-CoV-2						1H22: Interim data
		Internal	Undisclosed targets						

Partnered			
	VB10.NEO (individualized)	Melanoma, lung, bladder, renal, head and neck	Genentech <sup>1</sup> A Menniere of the Rocke Group NEKTAR <sup>2</sup>
Oncology	VB10.NEO (individualized)	Locally advanced and metastatic tumors	Genentech <sup>1</sup> A Member of the Roche Group
	Regeneron (programs 1 – 3) (off-the-shelf)	Undisclosed	REGENERON <sup>5</sup>
Infectious Disease	Regeneron (programs 4 - 5)	Undisclosed	REGENERON <sup>5</sup>

1. Genentech has an exclusive license to VB10.NEO; 2. Collaboration with Adaptive Biotechnologies on SARS-CoV-2 T cell vaccine; 5. Collaboration with Regeneron


## Vaccibody<sup>™</sup> APC-targeting platform is designed to induce a rapid, broad and lasting immune response

- Targets Antigen Presenting Cells (APCs) to induce T cells and B cells to combat cancer and infectious disease
- Ability to change the targeting unit enables different immune response profiles that can be tailored to specific diseases
- Delivery platform is agnostic to DNA, mRNA, viral vector vaccines
- Potential for combination therapies




We have achieved this by combining selected genes to encode novel vaccine molecules with desired properties

## Unique MoA stimulates both killer T cells and neutralizing antibodies for a potent, disease-specific response




### MIP-1a targeted Vaccibody induces effective crosspresentation resulting in broad, strong CD8 T cell responses




Vaccibody's unique ability to achieve controlled cross-presentation by specific APC receptor targeting induces broader and stronger CD8 responses than non-targeted vaccine technologies

### Nykode's modular platform enables generation of multiple specific and innovative products




## VB10.NEO: Fully individualized neoantigen based cancer vaccine demonstrates strong, targeted immune response

- Finalized enrollment VB N-01; 5 indications, <50 pt</li>
- Initiated VB N-02, in collaboration with Genentech; > 10 indications, 2 doses, combo with atezolizumab, ~40 patients
- Demonstrated ability to raise a broad, strong and targeted neoantigen-specific immune response
- Correlation between vaccine-induced immune responses and clinical responses
- Vaccine was well-tolerated



### VB10.16: Therapeutic off-the-shelf HPV16 vaccine currently in Phase 2


- Finalized Phase I/IIa study with VB10.16 monotherapy in HPV16+ precancerous cervical lesions, VB C-01
- Ongoing Phase II study of VB10.16 + atezolizumab in advanced cervical cancer, VB C-02
- Fully owned by Nykode



## VB10.16: strong T cell responses with significant correlation to lesion size regression, VB C-01

 All patients in the expansion cohort elicited a strong HPV16-specific T cell response


 Highly significant correlation between vaccine-induced T cell responses and lesion size regression across all cohorts




### VB10.16: strong CD8 T cell responses in patients, VB C-01

CD8 T cell response measured in 3 ٠ patients with CD4 depleted IFN-v ELISpot

Up to 100% of the HPV16 E7 and E6-specific IFN-y response was contributed by CD8 T cells, confirming effective crosspresentation by chemokinereceptor targeting





p023 p025 p027


20. %

p023 p025 p027


## VB10.16: Strong additional clinical data as monotherapy in precancerous lesions, VB C-01

#### VB10.16 as a monotherapy in HPV16positive, precancerous cervical lesions induces:

- Lesion size reduction in all patients in expansion cohort followed >4 months
- CIN regression to CIN1 or no CIN in 10 patients
- HPV16 and/or p16 clearance in 8 patients
- Well tolerated. No SAEs.
- Upregulation of PD-L1 in the lesions post vaccination, providing scientific rationale for combination with anti-PD-1/PD-L1 in cancer patients




UPREGULATION OF PD-L1 IN RESPONSE TO VACCINATION




### **VB10.16: Summary and next steps**


- Finalized Phase I/IIa study with VB10.16 monotherapy in HPV16+ precancerous cervical lesions
  - Demonstrated ability to induce strong HPV16 specific T cell responses
  - Strong correlation between vaccine induced T cell responses and lesion size reduction
  - Data from PD-L1 upregulation in monotherapy study provide scientific rationale for combination of anti-PD-1/PD-L1
- Ongoing Phase II study of VB10.16 + atezolizumab in advanced cervical cancer
  - interim safety analysis completed; support continuation
  - Enrollment completed Q1 2022
  - release of interim clinical data on track; expected 1H 2022
- Potential to expand scope to several HPV driven cancer types, including head and neck cancer



### Two COVID vaccine candidates currently in a Phase 1/2 study




## VB10.2210 includes a large set of conserved, validated T cell epitopes from 8 SARS-CoV-2 genes



- Spike is the main surface protein and the focus for neutralizing antibody responses
- However, T cell responses can recognize all viral proteins and thus Spike constitutes a limited source for optimal T cell responses
- High concentration of mutations in Spike are evading Spike-specific antibody responses and reduces the Spike-specific T cell responses against variants
- Adaptive biotechnologies has mapped TCR from >6500 Covid-19 patients and matched the T cell epitope specificity across the entire SARS-CoV-2 genome
- VB10.2210 is designed to induce a broad T cell response against multiple conserved and immunogenic epitopes identified by Adaptive Biotechnologies and includes epitopes from Spike and seven additional non-Spike antigens not affected by mutations in the VoC
- Intended to be used as a universal diverse booster Covid vaccine

. 3'


## VB10.2210 induces strong CD8 T cell responses in preclinical models



- VB10.2210 induces strong CD8 T cell responses after 1 vaccination against in humanized mice
- The strong T cell responses observed in two additional mice models show the breadth of the T cell response independent of HLA selection


## Phase 1/2 trial investigating two candidates as a diverse booster in previously vaccinated subjects

- A Phase 1/2, open label, dose escalation trial
- First subject with RBD candidate dosed Nov. 3, 2021; first patient with T cell candidate dosed Dec. 27, 2021
- Results expected during 1H 2022



# Financial overview

### Strong financial foundation for achieving our vision



- Financially well positioned to grow and execute the Company's strategy over the next years
- Strong balance sheet
  - 3Q 2021 liquidity of \$189 mill
  - Upfront payments totaling \$50 mill under Regeneron agreement received 4Q 2021<sup>1)</sup>
  - Milestone payment of \$20 mill for initiation of Phase 1b trial in 2H 2021 received 1Q 2022

#### Near-term catalysts 1H 2022



#### **Wholly-Owned Oncology**

- Phase 2 trial in HPV16+ cervical cancer (VB10.16)
  - Interim clinical data on 18 patients up to week 18
  - Expand into additional indications

#### COVID-19

- Phase 1/2 SARS-CoV-2 trial evaluating Nykode's two vaccine candidates (VB10.COV2)
  - Interim clinical data measuring T cell and antibody responses in previously vaccinated subjects

#### Other

· Update on manufacturing setup strategy

### UNLOCKING THE FUTURE OF MEDICINE

Contact: Michael Engsig CEO IR@vaccibody.com

Nykode Therapeutics | Company presentation | Non-confidential